The European Medicines Agency’s (EMA) Pharmacovigilance Risk Assessment Committee (PRAC) has concluded a comprehensive review of semaglutide-containing medications following growing concerns about a potential link to vision loss.
Breaking News
ViGeneron Rebrands as VeonGen, Earns FDA RPDD for Gene TherapyJun 16, 2025VeonGen Therapeutics has officially announced its rebranding from ViGeneron, marking a strategic transformation into a clinical-stage genetic medicine company dedicated to developing innovative gene therapies for diseases with high unmet medical needs.
Genetic Research Offers New Hope for Patients with Inherited Retinal DiseasesJun 02, 2025Researchers at the University of Oklahoma are advancing the understanding of inherited retinal diseases (IRDs) through genetic mapping that may lead to more accurate diagnoses and lay the groundwork for future treatments.
2024 Recap: Top 8 FDA Approvals in Ophthalmology Dec 16, 2024The year 2024 has been a pivotal one for ophthalmology, with several novel FDA approvals introducing innovative treatments and technologies to the field